Core Points - The company Huibei Huisheng Biotechnology Co., Ltd., a subsidiary of Huisheng Bio, has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its new veterinary drug "Yin Qiao Lan Qin Oral Solution" [1] Summary by Category - **Regulatory Approval** - The Ministry of Agriculture and Rural Affairs approved the joint application for the new veterinary drug [1] - The new veterinary drug registration certificate was issued on September 26, 2025 [1]

格隆汇9月30日丨回盛生物(300871.SZ)公布，根据《兽药管理条例》和《兽药注册办法》的规定，经中 华人民共和国农业农村部审查，批准武汉回盛生物科技股份有限公司子公司湖北回盛生物科技有限公司 与其他单位联合申报的"银翘蓝芩口服液"为新兽药，农业农村部于2025年9月26日核发了《新兽药注册 证书》。 ...

Core Viewpoint - In 2025, Wuhan Huisheng Biotechnology Co., Ltd. and its subsidiary obtained a new veterinary drug registration certificate for "Yinqiao Lianqin Oral Solution," which is effective against respiratory diseases in poultry, particularly those caused by external wind-heat [1] Company Summary - The new veterinary drug is classified as a Class III new veterinary drug with a monitoring period of three years [1] - The drug is specifically designed to treat colds in chickens caused by external wind-heat, addressing the prevalent respiratory diseases in poultry [1] - The successful development of this new drug reflects the company's commitment to innovation and enhances its portfolio of traditional Chinese medicine products [1] Industry Summary - There is a limited availability of compliant, green, and antibiotic-free drugs for poultry respiratory diseases, making this new product significant for the industry [1] - The introduction of this drug aligns with industry development requirements and is expected to improve the company's competitiveness in the market [1] - The product must obtain a veterinary drug approval number before it can be marketed [1]